Astellas launches Global Health Foundation
Japanese drug major Astellas Pharma (TYO: 4503) has announced the launch of the Astellas Global Health Foundation (AGHF), a new international philanthropic organization dedicated to improving access to health in underserved global communities.
Key areas of focus for the AGHF initially will be neglected tropical and communicable diseases, children's health and mental health in low-income communities and low-and middle-income countries where Astellas, a company dedicated to improving the health of people around the world, does not have a commercial presence. Additionally, the AGHF will fund programs that build healthier communities and provide disaster preparedness and relief in these same geographies.
The Astellas Global Health Foundation merges three former philanthropic entities – the Astellas USA Foundation (AUSF), the Astellas European Foundation (AEF), and the Astellas Asia-Oceania Foundation (AAOF) – into one organization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze